{"id":"W3211713559","doi":"10.1136/jitc-2021-sitc2021.459","title":"459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pembrolizumab; TIGIT; Medicine; Internal medicine; Oncology; Lung cancer; Antibody; Phases of clinical research; Chemotherapy; Immunotherapy; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002120706,0.001631817,0.002911883,0.0004842909,0.0007373175,0.001539481,0.001138805,0.002106431,0.005298207],"category_scores_gemma":[0.0009995935,0.001041883,0.003038255,0.0003824149,0.001103853,0.001027418,0.0003967864,0.004887594,0.001421934],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001574687,"about_ca_system_score_gemma":0.003099737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002522287,"about_ca_topic_score_gemma":0.005525161,"domain_scores_codex":[0.9992895,0.0003185842,0.00003357113,0.0001148334,0.00007584284,0.0001675408],"domain_scores_gemma":[0.999169,0.0001002863,0.0001201156,0.00007377638,0.00008069167,0.0004562566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8671164,0.08290637,0.002030337,0.0005052891,0.001608176,0.0001001553,0.0001581117,0.001130191,0.02041328,0.0001482634,0.002881163,0.02100226],"study_design_scores_gemma":[0.7404937,0.249941,0.004208568,0.00002450244,0.000545901,0.00008334641,0.00003933076,0.0007693488,0.002060069,0.0001332907,0.001666876,0.00003417448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826066,0.002269567,0.000784747,0.0007439613,0.0005567694,0.007812671,0.002420326,0.0001687379,0.002636585],"genre_scores_gemma":[0.9808843,0.00161927,0.002134827,0.002062539,0.0003997886,0.005830715,0.003024356,0.00006246431,0.003981673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005298207,"threshold_uncertainty_score":0.01772422,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01345953156058194,"score_gpt":0.2621275120378249,"score_spread":0.248667980477243,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}